ArticleOncology letters2022

Efficacy and safety of anlotinib as a third-line treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.

Bowen Zha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.